SCHEMBL14559366

SCHEMBL14559366

CC(=O)NCC1CCCN(C)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FAP Q12884 2/20 0.43
DPP4 P27487 1/20 0.43
PREP P48147 1/20 0.43
MTNR1A P48039 2/20 0.42
MTNR1B P49286 2/20 0.42
GFER P55789 1/20 0.41
CACNA1H O95180 1/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KDM4E B2RXH2 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
EPHX1 P07099 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17207607 1.00 CCR3 (0.44) CCR3SMN1; SMN2FAPDPP4PREP
SCHEMBL14155724 1.00 CCR3 (0.44) CCR3SMN1; SMN2FAPDPP4PREP
SCHEMBL25808542 0.89 MTNR1A (0.44) CCR3FAPDPP4PREPMTNR1A
SCHEMBL5740884 0.89 MTNR1A (0.44) CCR3FAPDPP4PREPMTNR1A
SCHEMBL4874313 0.88 SMN1; SMN2 (0.40) CCR3SMN1; SMN2FAPDPP4PREP
SCHEMBL25051622 0.86 CYP2D6 (0.50) SMN1; SMN2GFERPOLBALDH1A1KDM4E
SCHEMBL13436977 0.84 TDP1 (0.55) SMN1; SMN2GFERALDH1A1KDM4EEPHX1
SCHEMBL19658450 0.83 PREP (0.48) SMN1; SMN2FAPDPP4PREPGFER
SCHEMBL15841168 0.83 MTNR1A (0.47) FAPDPP4PREPMTNR1AMTNR1B
SCHEMBL3833189 0.81 KDM4E (0.46) CCR3FAPDPP4PREPPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019193516-A2 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 WO disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
EP-2069327-B1 NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INT (DE) 2013-10-16 EP disclosed
US-7186739-B2 Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas IMMUPHARMA (FRANCE) SA (FR) 2007-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 CCR3 1147/4885SMN1; SMN2 1221/4885FAP 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.